HomeEXAS • NASDAQ
add
Exact Sciences Corp
Previous close
$101.13
Day range
$101.12 - $101.61
Year range
$38.88 - $101.87
Market cap
19.23B USD
Avg Volume
6.84M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 850.74M | 20.05% |
Operating expense | 584.94M | 14.70% |
Net income | -19.59M | 48.76% |
Net profit margin | -2.30 | 57.41% |
Earnings per share | 0.24 | 287.35% |
EBITDA | 54.87M | 51.27% |
Effective tax rate | -10.35% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.00B | -1.77% |
Total assets | 5.90B | -12.57% |
Total liabilities | 3.40B | -3.94% |
Total equity | 2.50B | — |
Shares outstanding | 189.47M | — |
Price to book | 7.66 | — |
Return on assets | -0.04% | — |
Return on capital | -0.05% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -19.59M | 48.76% |
Cash from operations | 219.92M | 58.54% |
Cash from investing | -86.45M | -5.80% |
Cash from financing | -1.53M | -577.88% |
Net change in cash | 131.94M | 124.96% |
Free cash flow | 194.64M | 80.56% |
About
Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
In November 2025, Abbott Laboratories agreed to acquire Exact Sciences in a deal worth roughly $21 billion. Wikipedia
CEO
Founded
Jan 1, 1995
Headquarters
Website
Employees
6,950
